Zheng Quan Shi Bao Wang·2025-11-21 13:40Summary of Key Points Core Viewpoint - A total of 33 stocks received buy ratings from institutions today, with notable first-time attention on Chao Hong Ji, Wei Hong Co., and Zhong Wei Company [1][2]. Institutional Ratings - 33 stocks received buy ratings, with the highest attention on Jingxin Pharmaceutical and Baoxiniang, each having one buy rating record [1]. - Among the rated stocks, 13 provided future target prices, with 9 stocks showing an upside potential exceeding 20%. Guangxun Technology has the highest upside potential at 81.99%, with a target price of 99.00 yuan compared to the latest closing price of 54.40 yuan [1][2]. - Other stocks with significant upside potential include Antu Biology at 43.13% and Enhua Pharmaceutical at 35.08% [1][2]. Market Performance - The average decline for stocks with buy ratings today was 2.80%, underperforming the Shanghai Composite Index. Only 5 stocks saw price increases, with the largest gains from Fulei New Materials (2.63%), Lianying Medical (2.15%), and Top Group (0.84%) [1][2]. - Stocks with the largest declines included Xiamen Tungsten New Energy (-9.09%), Aopu Mai (-7.02%), and Minsheng Health (-6.59%) [1][2]. Industry Focus - The pharmaceutical and biotechnology sector is the most favored, with 8 stocks including Minsheng Health and Enhua Pharmaceutical making the buy rating list. The electronics and textile sectors also attracted attention, with 4 and 3 stocks respectively [2][3].